CommercialCoverageMedium impact
Coverage of Meningococcal Groups A, B, C, W, and Y Vaccine (PENMENVY) for Commercial Members (Retroactively Effective 02/14/2025)
Independence Blue Cross·Family Medicine, Internal Medicine, Pediatrics +2 more·News & Announcements
Effective date
Feb 14, 2025
We identified it
Jun 19, 2026
Summary
A new meningococcal vaccine (PENMENVY) covering groups A, B, C, W, and Y is now covered for commercial members, with coverage retroactively effective from February 14, 2025. This expands vaccination options beyond previously covered individual meningococcal vaccines.
Action Required
Immediately: Billing team should verify that PENMENVY vaccine claims for commercial members can be processed retroactively to February 14, 2025. Update vaccination protocols and inform providers that this combination vaccine is now covered for commercial plans. Ensure proper coding and billing procedures are in place for this new vaccine coverage.